- $849.06m
- $857.48m
- $105.76m
- 50
- 14
- 22
- 18
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 19.99 | ||
| PEG Ratio (f) | 0.27 | ||
| EPS Growth (f) | 281.03% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 13.41 | ||
| Price to Tang. Book | 13.47 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 8.03 | ||
| EV to EBITDA | 48.41 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 15.26% | ||
| Return on Equity | 50.89% | ||
| Operating Margin | 15.28% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 20.95 | 7.34 | 0.79 | 113.45 | 105.76 | 126.5 | 238 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | +1.15 | +875 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Gyre Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of F351 (Hydronidone) for the treatment of MASH-associated fibrosis in the United States. It is also advancing a diverse pipeline in the PRC through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. F351 is a structural derivative of ETUARY. F573 is its clinical-stage product candidate for the treatment of acute/acute-on-chronic liver failure (ALF/ACLF) in Phase 2 clinical trials in the PRC. F528 is a preclinical-stage candidate targeting chronic obstructive pulmonary disease. F230 is a clinical-stage compound for the treatment of pulmonary arterial hypertension. It is focused on commercializing therapies for the treatment of pulmonary fibrosis through its two therapeutic products: ETUARY (pirfenidone) and nintedanib. It is also focused on commercializing the avatrombopag product.
Directors
- Augustine Lawlor NEC (65)
- Nassim Usman PRE (61)
- Seline Miller CFO
- Tom Knudsen SVP
- Grant Blouse CSO
- Jeanne Jew DRC (58)
- Errol De Souza IND (67)
- Andrea Hunt IND (61)
- Geoffrey Ling IND (64)
- Sharon Tetlow IND (61)
- Edward Williams IND (65)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- March 7th, 1997
- Public Since
- April 12th, 2006
- No. of Shareholders
- 44
- No. of Employees
- 574
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 93,612,442
- Address
- 12770 High Bluff Drive, Suite 150, SAN DIEGO, 92130
- Web
- https://www.gyretx.com/
- Phone
- +1 6199493681
- Auditors
- GRANT THORNTON ZHITONG CERTIFIED PUBLIC ACCOUNTANTS LLP
Upcoming Events for GYRE
Gyre Therapeutics Inc Annual Shareholders Meeting
Gyre Therapeutics Inc Annual Shareholders Meeting
Q2 2025 Gyre Therapeutics Inc Earnings Release
Similar to GYRE
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Gyre Therapeutics share price?
As of Today at 20:59 UTC, shares in Gyre Therapeutics are trading at $9.07. This share price information is delayed by 15 minutes.
How has the Gyre Therapeutics share price performed this year?
Shares in Gyre Therapeutics last closed at $9.07 and the price had moved by -44.46% over the past 365 days. In terms of relative price strength the Gyre Therapeutics share price has underperformed the S&P500 Index by -48.73% over the past year.
What are the analyst and broker recommendations for Gyre Therapeutics?
The overall consensus recommendation for Gyre Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Gyre Therapeutics dividend yield?
Gyre Therapeutics does not currently pay a dividend.
Does Gyre Therapeutics pay a dividend?
Gyre Therapeutics does not currently pay a dividend.
When does Gyre Therapeutics next pay dividends?
Gyre Therapeutics does not currently pay a dividend.
How do I buy Gyre Therapeutics shares?
To buy shares in Gyre Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Gyre Therapeutics?
As of the previous close price of $9.07, shares in Gyre Therapeutics had a market capitalisation of $849.06m.
Where are Gyre Therapeutics shares listed?
Here are the trading details for Gyre Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: GYRE
What kind of share is Gyre Therapeutics?
Based on an overall assessment of its quality, value and momentum Gyre Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Gyre Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Gyre Therapeutics is $20.00. That is 120.51% above the last closing price of $9.07.
Analysts covering Gyre Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of $0.12 for the next financial year.
Find out moreWhat is the trend in the Gyre Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Gyre Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -32.73%.
As of the last closing price of $9.07, shares in Gyre Therapeutics were trading -23.52% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Gyre Therapeutics PE Ratio?
The Gyre Therapeutics PE ratio based on its reported earnings over the past 12 months is 19.99. The shares last closed at $9.07.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Gyre Therapeutics?
Gyre Therapeutics' management team is headed by:
- Augustine Lawlor - NEC
- Nassim Usman - PRE
- Seline Miller - CFO
- Tom Knudsen - SVP
- Grant Blouse - CSO
- Jeanne Jew - DRC
- Errol De Souza - IND
- Andrea Hunt - IND
- Geoffrey Ling - IND
- Sharon Tetlow - IND
- Edward Williams - IND